PharmaFocus Today – Page 48 – media

Sinovac’s quadrivalent influenza vaccine has been approved to cover people aged 6 months and above

　　Shanghai Securities News China SecuritiesNet News (Reporter Zhang Xue) The reporter learned from Sinovac Holdings on October 10 that recently, Beijing Sinovac BiotechQuadrivalent influenza virusThe National Medical Products Administration (NMPA) has approved an expanded age range for the Sinovac quadrivalent influenza vaccine, expanding its coverage to include individuals aged 6-35 months, in addition to those aged 3 years and above. With this expanded age range, the Sinovac quadrivalent influenza vaccine now covers all ages 6 months and older and is currently in use in nearly 20 countries and regions worldwide. 　　Infants and young children aged 6-35 months are at high risk for influenza- related complications. Flu vaccination is the most effective and economical way to prevent influenza and reduce the risk of complications. Furthermore, families are a key venue for influenza transmission. Studies have shown that 26% of influenza infections can be attributed to transmission within the family, and the ...
- Source: drugdu
- 206
- October 11, 2025
No more chemotherapy after gastric cancer surgery? Henlius’s successful clinical trial of Hans-like therapy is the world’s first

　　This newspaper (Reporter Jin Wanxia) reported on October 9 that Shanghai Fuhong Hanlin Biotech Co., Ltd. (hereinafter referred to as ” Fuhong Hanlin “) announced that the company’s Phase III clinical study of its self-developed innovative PD-1 inhibitor Hanseluzumab (slulizumab) combined with chemotherapy for neoadjuvant/monoadjuvant treatment of gastric cancer has met the pre-set superiority criteria and the treatment regimen has a good safety profile. This is the world’s first treatment regimen for gastric cancer in the perioperative (preoperative/postoperative) period to replace postoperative adjuvant chemotherapy with a single immunotherapy agent, achieving a major breakthrough in this field. 　　In light of these data, Henlius intends to advance its marketing authorization application for this indication. Dr. Zhu Jun, Executive Director and CEO of Henlius, stated, “Gastrointestinal cancer is a core area of focus for Henlius. We will actively promote the translation of our research findings to benefit patients as soon as possible, and ...
- Source: drugdu
- 134
- October 11, 2025
Multimodal nanocarriers offer targeted solutions for tumor treatment

Cancer remains a leading cause of global morbidity and mortality. Traditional therapies like chemotherapy and radiotherapy are often limited by their lack of specificity, leading to systemic toxicity and the emergence of drug resistance. Nanoparticles, with dimensions ranging from 1 to 100 nm, offer a sophisticated solution. Their unique physicochemical properties allow them to navigate biological barriers and can be engineered for active targeting (e.g., using ligands for overexpressed cancer cell receptors) or passive targeting (exploiting the Enhanced Permeability and Retention effect of tumor vasculature). The cellular uptake of these nanocarriers is a critical process, primarily occurring through various endocytic pathways such as clathrin-mediated, caveolin-mediated, and macropinocytosis, followed by crucial intracellular steps like endosomal or lysosomal escape to ensure the therapeutic cargo reaches its target intact. Nanocarriers in drug-delivery systems for cancer treatment A diverse arsenal of nanocarriers has been developed, each with distinct advantages and limitations. Liposomes, spherical phospholipid ...
- Source: drugdu
- 116
- October 11, 2025
Drug Combo Effective Against Advanced Prostate Cancer

By Dennis Thompson HealthDay ReporterFRIDAY, Oct. 10, 2025 (HealthDay News) — A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom advance, according to findings published Oct. 7 in the journal Nature Medicine. The combination was even more effective among men with genetic mutations driving their prostate cancer, researchers noted. “Although current standard treatments are very effective for the majority of patients with advanced prostate cancer, a small but very significant proportion of patients have limited benefit,” said lead researcher Dr. Gerhardt Attard, chair of medical oncology with the University College London Cancer Institute. “By combining with niraparib we can delay the cancer returning and hopefully significantly prolonging life expectancy,” he said in a news release. Niraparib is a “maintenance” drug approved to keep certain types of cancer ...
- Source: drugdu
- 101
- October 11, 2025
Scientists have developed a nano vaccine to prevent animal cancer, which can effectively inhibit the spread of cancer cells

According to a new research published in the journal Cell Reporting Medicine on the 10th, the team of the University of Massachusetts Amherst in the United States has developed a nano vaccine to prevent animal cancer, which has shown significant effects in preventing mouse melanoma, pancreatic cancer and triple negative breast cancer. Among the mice vaccinated with this vaccine, up to 88% remained tumor free (the specific proportion varies depending on the type of cancer), and the vaccine effectively inhibited the spread of cancer cells, even completely preventing metastasis in some cases. This platform technology has broad applicability and can be used for the prevention and treatment of various types of cancer, and is expected to be used in high-risk cancer populations in the future. Previous team research has demonstrated that this nanoparticle based drug design can shrink and eliminate tumors in mice. This study further confirms that the ...
- Source: drugdu
- 98
- October 11, 2025
“Efficient research and development+cost advantage” recognized, innovative drugs surging overseas trend

Recently, Nuocheng Jianhua and global biopharmaceutical company Zenas jointly announced a global authorization cooperation agreement, with a potential total transaction amount of over 2 billion US dollars, adding another heavyweight footnote to China’s innovative drugs going global. Since 2025, the trend of innovative drugs going global has continued to heat up. Previously, leading pharmaceutical companies such as Hengrui Pharmaceutical and Xinda Biotechnology have successively achieved international breakthroughs in technology and market through overseas authorization. Analysts believe that the continuous increase in the amount and quantity of foreign authorizations for innovative drugs in China is an inevitable trend after the research and development capabilities in this field are globally recognized. In the past few years, the product data of domestic innovative pharmaceutical companies has continuously verified their clinical value, from early individual enterprise breakthroughs to collective global cooperation today. Essentially, it is the global market’s recognition of Chinese pharmaceutical companies’ “efficient ...
- Source: drugdu
- 212
- October 11, 2025
FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis Treatment

FDA announced its approval of Boehringer Ingelheim’s Jascayd (nerandomilast) tablets for the treatment of idiopathic pulmonary fibrosis (IPF). Jascayd’s approval makes it the first approved new therapy treatment for IPF in over 10 years, and with IPF being a rare, serious, and progressive disease with no cure and limited treatments, the approval marks a significant step in supporting those suffering from the disease. FDA’s approval of Jascayd was a data backed decision FDA based its approval on results collected from two Phase III trials, Fibroneer-IPF and Fibroneer-ILD.1 Jascayd’s efficiency was evaluated in both randomized, double-blind, placebo-controlled trials of adults with IPF.1 The primary endpoint was the absolute change from baseline in Forced Vital Capacity, which is the maximum amount of air a person can forcefully exhale after taking the deepest possible breath.1 Results indicated that Participants administered with Jascayd had significantly reduced FVC decline when compared to participants treated with ...
- Source: drugdu
- 126
- October 10, 2025
Popular Painkiller Less Effective, More Risky Than Thought, Evidence Review Says

By Dennis Thompson HealthDay ReporterTHURSDAY, Oct. 9, 2025 (HealthDay News) — A widely prescribed opioid painkiller is not all it’s cracked up to be, a new evidence review has concluded. The opioid painkiller tramadol does little to reduce moderate to severe pain, according to results published Oct. 7 in the journal BMJ Evidence Based Medicine. At the same time, tramadol increases a person’s risk of serious side effects, including heart disease and pre-cancerous cells, researchers found. The drug’s use should be minimized, and guidelines that recommend it reconsidered, the research team concluded. “The potential harms associated with tramadol use for pain management likely outweigh its limited benefits,” wrote the research team led by Jehad Ahmad Barakji of the Center for Clinical Intervention Research at Rigshospitalet in Copenhagen, Denmark. Tramadol is a dual-action opioid, researchers said in background notes. It works on the usual opioid receptors in the brain, much like ...
- Source: drugdu
- 122
- October 10, 2025
PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies

PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP manufacturing, aiming to accelerate non-viral cell and gene therapies for the benefit of patients. PlasmidFactory GmbH, a leading European CDMO for plasmid and Minicircle DNA, brings more than 25 years of experience and over 3,500 DNA constructs delivered worldwide. The Fraunhofer IZI contributes extensive translational capabilities in immuno-oncology, regenerative medicine, and advanced cell manufacturing. Together, they are accelerating the development of next-generation, virus-free genetic engineering platforms while maintaining the highest quality and regulatory standards. In the past, the two partners have already successfully established new manufacturing processes for CAR-T cells at Fraunhofer IZI and conducted joint research projects on virus-free gene transfer, which served as the foundation for the production of clinical cell products. By building on our long-standing collaboration, this partnership ...
- Source: drugdu
- 121
- October 9, 2025
More Patients Using GLP-1 Drugs Prior To Weight-Loss Surgery

By Dennis Thompson HealthDay ReporterWEDNESDAY, Oct. 8, 2025 (HealthDay News) — Many more folks fighting excess weight are using weight-loss drugs like Ozempic or Zepbound to cut pounds before undergoing bariatric surgery, a new study says. The use of these drugs before surgery rose 16-fold among patients preparing for weight-loss surgery, researchers reported Sunday at the American College of Surgeons’ annual meeting in Chicago. “While patients previously believed they had to choose between GLP-1 receptor agonists and surgery, we’re now seeing that people are using both,” said lead researcher Dr. Stefanie Rohde, a general surgery resident at the Ohio State University Wexner Medical Center in Columbus. “We know that patients can use GLP-1s after bariatric surgery to amplify their weight loss,” Rohde said in a news release. “But all of this is still very new in terms of how to manage patients effectively.” For the study, researchers looked at the ...
- Source: drugdu
- 153
- October 9, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.